Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | viral clearance |
| favipiravir | 6 | - | 1.25 [0.21; 7.62], 1 RCT, I2=0%
inconclusive result | 1.12 [0.02; 62.74], 1 RCT, I2=0%
inconclusive result | 0.98 [0.21; 4.57], 2 RCTs, I2=32%
inconclusive result | |
| chloroquine and derivatives | 3 | - | - | 0.66 [0.04; 11.04], 2 RCTs, I2=0%
inconclusive result | OBS 16.33 [2.80; 95.27], 1 study, I2=0%
unassessable degree of certainty | |
| remdesivir | 2 | - | 1.29 [1.12; 1.49], 1 RCT, I2=0%
unassessable degree of certainty | 0.55 [0.36; 0.84], 1 RCT, I2=0%
unassessable degree of certainty | - | |
| darunavir cobicistat | 1 | 2.07 [0.06; 66.79], 1 RCT, I2=0%
inconclusive result | - | 1.00 [0.02; 53.89], 1 RCT, I2=0%
inconclusive result | 0.82 [0.36; 1.87], 1 RCT, I2=0%
inconclusive result | |
| hydroxychloroquine plus macrolides | 1 | - | - | OBS 1.14 [0.56; 2.32], 1 study, I2=0%
inconclusive result | - | |
| nirmatrelvir / ritonavir (Paxlovid) | 1 | - | - | - | - | |
| umifenovir (arbidol) | 1 | - | - | - | - | |
| Amantadine | 0 | - | - | - | - | |
| ASC09/ritonavir | 0 | - | - | - | - | |
| azithromycin | 0 | - | - | - | - | |
| azvudine | 0 | - | - | - | - | |
| baloxavir marboxil | 0 | - | - | - | - | |
| bromhexine | 0 | - | - | - | - | |
| carrimycin | 0 | - | - | - | - | |
| danoprevir / ritonavir | 0 | - | - | - | - | |
| doxycycline | 0 | - | - | - | - | |
| Emtricitabine/tenofovir plus colchicine plus rosuvastatin | 0 | - | - | - | - | |
| Ensitrelvir (XOCOVA) | 0 | - | - | - | - | |
| favipiravir plus interferon | 0 | - | - | - | - | |
| fluvoxamine | 0 | - | - | - | - | |
| Interferon plus lopinavir/ritonavir | 0 | - | - | - | - | |
| ivermectin | 0 | - | - | - | - | |
| leronlimab | 0 | - | - | - | - | |
| lopinavir / ritonavir plus ribavirin | 0 | - | - | - | - | |
| lopinavir/ritonavir | 0 | - | - | - | - | |
| lopinavir/ritonavir plus chloroquine | 0 | - | - | - | - | |
| Lopinavir/ritonavir plus hydroxychloroquine | 0 | - | - | - | - | |
| lopinavir/ritonavir plus interferon ß-1a | 0 | - | - | - | - | |
| lopinavir/ritonavir, ribavirin and interferon beta-1b | 0 | - | - | - | - | |
| molnupiravir | 0 | - | - | - | - | |
| niclosamide | 0 | - | - | - | - | |
| nitazoxanide | 0 | - | - | - | - | |
| opaganib | 0 | - | - | - | - | |
| oseltamivir | 0 | - | - | - | - | |
| oseltamivir plus chloroquin | 0 | - | - | - | - | |
| ribavirin | 0 | - | - | - | - | |
| ritonavir | 0 | - | - | - | - | |
| sofosbuvir | 0 | - | - | - | - | |
| sofosbuvir and daclatasvir | 0 | - | - | - | - | |
| sofosbuvir and ledipasvir | 0 | - | - | - | - | |
| tenofovir/emtricitabine | 0 | - | - | - | - | |
| tenofovir/emtricitabine plus hydroxychloroquine | 0 | - | - | - | - | |
| tranexamic acid | 0 | - | - | - | - | |
| tranilast | 0 | - | - | - | - | |
| triazavirin | 0 | - | - | - | - | |
| zinc | 0 | - | - | - | - | |
